Challenges and Prospects for Eradication of <i>Helicobacter pylori</i>: Targeting Virulence Factors, Metabolism, and Vaccine Innovation

<i>Helicobacter pylori</i> is a Gram-negative bacterium that infects almost half of the global population and is linked to gastric conditions like peptic ulcers and gastric cancer, as well as other diseases such as neurological disorders, cardiovascular problems, and iron deficiency anem...

Full description

Saved in:
Bibliographic Details
Main Authors: Adrian Bakiera, Anita Solarz, Marika Kowalczyk, Halina Cichoż-Lach, Izabela Korona-Głowniak
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Pathogens
Subjects:
Online Access:https://www.mdpi.com/2076-0817/14/7/619
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<i>Helicobacter pylori</i> is a Gram-negative bacterium that infects almost half of the global population and is linked to gastric conditions like peptic ulcers and gastric cancer, as well as other diseases such as neurological disorders, cardiovascular problems, and iron deficiency anemia. Its survival in the acidic stomach environment is due to virulence factors like urease, flagella, and adhesion proteins (BabA, SabA). Current treatments involve a combination of antibiotics (clarithromycin, metronidazole, amoxicillin, tetracycline) and proton pump inhibitors, but increasing antibiotic resistance, especially to clarithromycin and metronidazole, poses a major challenge. Resistance mechanisms include mutations in drug targets, efflux pump overexpression, and enzymatic degradation of antibiotics. This has prompted exploration of alternative therapies targeting bacterial processes like urease activity, biofilm formation, and metabolic pathways (energy production, amino acid synthesis, iron acquisition). Natural compounds, such as chitosan and plant extracts, show promise in combating <i>H. pylori</i> growth and virulence. Vaccine development is also ongoing, with DNA vaccines showing potential for broad immune responses. However, no vaccine is yet close to widespread clinical use.
ISSN:2076-0817